{"id":"NCT01482962","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma","officialTitle":"A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-11","primaryCompletion":"2015-06-30","completion":"2017-12-18","firstPosted":"2011-12-01","resultsPosted":"2018-07-31","lastUpdate":"2018-07-31"},"enrollment":271,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsed Peripheral T-Cell Lymphoma","Refractory Peripheral T-Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Alisertib","otherNames":[]},{"type":"DRUG","name":"Pralatrexate","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Romidepsin","otherNames":[]}],"arms":[{"label":"Alisertib","type":"EXPERIMENTAL"},{"label":"Pralatrexate, or Romidepsin, or Gemcitabine","type":"ACTIVE_COMPARATOR"}],"summary":"This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent comparator outside the United States of America (USA) as supply was not available.","primaryOutcome":{"measure":"Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment","timeFrame":"Every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until progressive disease. Duration is approximately 3 years","effectByArm":[{"arm":"Alisertib","deltaMin":33,"sd":null},{"arm":"Pralatrexate, or Romidepsin, or Gemcitabine","deltaMin":45,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.038"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":151,"countries":["United States","Australia","Austria","Belarus","Belgium","Brazil","Bulgaria","Canada","Chile","Czechia","Denmark","Egypt","France","Germany","Hungary","Israel","Italy","Mexico","Netherlands","New Zealand","Peru","Poland","Portugal","Puerto Rico","Romania","Russia","Slovakia","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["30707661"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":137},"commonTop":["Anaemia","Neutropenia","Thrombocytopenia","Diarrhoea","Stomatitis"]}}